<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342690</url>
  </required_header>
  <id_info>
    <org_study_id>A6141122</org_study_id>
    <nct_id>NCT03342690</nct_id>
  </id_info>
  <brief_title>Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)</brief_title>
  <official_title>Drug Use Investigation Of Selara(Registered). Tablets(an Investigation For Chronic Heart Failure)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Secondary Data Collection Study; Safety And Effectiveness Of Selara Under Japanese Medical
      Practice
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted under the central registration system until the number of
      subjects who meet the conditions for registration reaches the target number of subjects. The
      patients will be observed up until Week 52.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with adverse events in participants with moderate renal impairment</measure>
    <time_frame>52 weeks from the start date</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with adverse event in participants</measure>
    <time_frame>52 weeks from the start date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of deaths (Overall mortality)</measure>
    <time_frame>52 weeks from the start date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of deaths (Cardiovascular deaths)</measure>
    <time_frame>52 weeks from the start date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of death (Overall mortality)</measure>
    <time_frame>52 weeks from the start date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of death (Cardiovascular deaths)</measure>
    <time_frame>52 weeks from the start date</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <description>Patients with CHF receiving Selara (eplerenone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.
Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions.</description>
    <arm_group_label>Eplerenone</arm_group_label>
    <other_name>Selara</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients who meet the inclusion criteria and who were registered to this study within
        14 days including the start date of treatment with this product will be subjects for this
        study
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients in whom treatment with this drug is for CHF. The indications at approval for
             this drug are as follows. When using this drug, refer to the latest package insert of
             this drug.

        Exclusion Criteria:

          -  Patients who were previously registered for this study. Patients who received
             eplerenone within the past three months regardless of the reason for use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Local Country Office</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6141122&amp;StudyName=Drug+Use+Investigation+Of+Selara%28registered%29.+Tablets%28an+Investigation+For+Chronic+Heart+Failure%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Selara</keyword>
  <keyword>Chronic Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

